Nohla is the leading developer of allogeneic cellular therapies for patients with hematologic malignances and other critical diseases. These differentiated product candidates are available off the shelf without the need for HLA matching. The company’s lead product, NLA101, is a hematopoietic cell graft consisting of ex vivo expanded CD34+ stem and progenitor cells derived from umbilical cord blood. Clinical results to date demonstrate that NLA101 provides rapid hematopoietic recovery, especially functional myelopoiesis for the prevention of infection. Founded in December 2015 with licensed technology developed and studied for over two decades at the Fred Hutchinson Cancer Research Center, Nohla’s proprietary technology is based on the density-dependent Notch ligand platform that enables ex vivo expansion and directed differentiation of hematopoietic stem and progenitor cells. These expanded cells have broad application across multiple cell types, indications and pipeline products.
In late 2016, Nohla completed a $43.5M Series A financing round led by new investor ARCH Venture Partners and included participation from 5AM Ventures and existing investor, the Jagen Group. The Series A round brings the total financing obtained since the Company’s inception to $64.6M.